Lorlatinib: where the agencies disagree
This page collects every recorded health technology assessment decision for one molecule across the agencies in our archive, and compares them. The comparison is the point: each agency publishes its own verdict, none publishes how that verdict sits against the others.
What the record shows
AOTMIT (Poland), DMC (Denmark) and HAS (France), among others, recommended or restricted lorlatinib, while CIPM (Spain) did not recommend it.
Assessment has run over 6.4 years, from 3 May 2019 at AWMSG (Wales) to 21 Oct 2025 at NICE (England).
NYE METODER (Norway) changed its position: not recommended on 13 Dec 2020, recommended by 22 May 2022, after a resubmission.
No assessment is on file from PHARMAC (New Zealand), which is among the eight highest-volume agencies here.
The file is active: 5 of 26 records date from 2023 or later.
7 distinct indication wordings are recorded for lorlatinib by the agencies that label one in English (AWMSG, NICE, PBAC and SMC).
3 of these 26 records carry a year of decision but no day, so any interval quoted here is approximate to within a year.
AWMSG (Wales) was first to assess lorlatinib, on 3 May 2019; AOTMIT (Poland) did not open a file until 3 Feb 2023 — a wide spread of 3.8 years between the earliest and latest system to look at it.
The record arrives in waves: 5 separate years each carry two or more decisions, spread across 7 years in total.
Restriction is doing real work here: 5 of 20 decisive outcomes narrowed lorlatinib to a subgroup rather than accepting or refusing it outright, at AOTMIT (Poland), HIRA (South Korea) and NICE (England) among others.
11 of the 12 agencies here assessed lorlatinib more than once, HIRA (South Korea) most often at 3 entries — repeat review is the norm for this molecule rather than the exception.
lorlatinib has been through 12 of the 18 agencies in this archive — among the most widely assessed molecules on file.
The full ledger for lorlatinib reads 12 recommended, 5 restricted, 3 not recommended and 2 no benefit, with 4 in other categories.
Decisions on file
| Agency | Date | Indication as recorded | Outcome | Source |
|---|---|---|---|---|
| DMC (Denmark) | 18 Jun 2025 | Behandling af voksne patienter med anaplastisk lymfomkinase-positiv (ALK-positiv), fremskreden ikke-småcellet lungecance… | Anbefalet | source |
| HIRA (South Korea) | 9 Jan 2025 | 역형성 림프종 인산화효소 (ALK)- 양성 전이성 비소세포폐암 | reimbursable only at the evaluated price (risk-share extension) | source |
| AOTMIT (Poland) | 3 Feb 2023 | programu lekowego Prezes Agencji rekomenduje objęcie refundacją produkt u leczniczego Lorviqua (lorlatynib) w programie … | recommended conditionally | source |
| HAS (France) | 5 Oct 2022 | Indication extension | SMR substantial · ASMR IV | source |
| CIPM (Spain) | 29 Sep 2022 | Indicaciones terapéuticas autorizadas: LORVIQUA en monoterapia está indicado para el tratamiento de pacientes adultos co… | not financed by the SNS · art. 92 d | source |
21 further decisions for lorlatinib, across 11 agencies, are not shown here. They include the most recent record on file, 21 Oct 2025 from NICE (England); its outcome is in the subscriber dataset. They link to 17 further source documents.
Related molecules
- ibrutinib — same ATC class L01E — Antineoplastics
- zanubrutinib — same ATC class L01E — Antineoplastics
- cabozantinib — same ATC class L01E — Antineoplastics
- selpercatinib — same ATC class L01E — Antineoplastics
- acalabrutinib — same ATC class L01E — Antineoplastics
- ribociclib — same ATC class L01E — Antineoplastics
Coverage: 26 decisions for lorlatinib from 12 agencies, 2019 to 2025. Data to 7 Sep 2026. ATC class L01E — Antineoplastics. How this page is produced. Compiled by Altima Partners; queries: sales@altimapartners.co.uk.